HC Wainwright Issues Optimistic Forecast for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Investment analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for Unicycive Therapeutics in a report issued on Tuesday, March 31st. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.05) per share for the quarter, up from their prior estimate of ($0.35). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q2 2026 earnings at ($0.52) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.76) EPS, FY2026 earnings at ($1.67) EPS, FY2027 earnings at ($0.90) EPS, FY2028 earnings at $1.60 EPS, FY2029 earnings at $5.70 EPS and FY2030 earnings at $7.45 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its earnings results on Monday, March 30th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.36).

Several other equities analysts have also issued reports on the company. Guggenheim decreased their price target on Unicycive Therapeutics from $46.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, March 27th. Finally, Westpark Capital assumed coverage on shares of Unicycive Therapeutics in a research report on Thursday, February 19th. They set a “buy” rating on the stock. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Unicycive Therapeutics Price Performance

Unicycive Therapeutics stock opened at $6.93 on Friday. The firm has a market cap of $174.91 million, a PE ratio of -3.19 and a beta of 1.81. The stock’s fifty day moving average price is $6.67 and its two-hundred day moving average price is $5.81. Unicycive Therapeutics has a one year low of $3.71 and a one year high of $11.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of UNCY. Vivo Capital LLC grew its stake in Unicycive Therapeutics by 57.4% in the 3rd quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock valued at $7,804,000 after purchasing an additional 652,901 shares during the period. Millennium Management LLC purchased a new position in Unicycive Therapeutics in the 4th quarter valued at approximately $5,856,000. Vanguard Group Inc. lifted its holdings in Unicycive Therapeutics by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock worth $2,873,000 after purchasing an additional 52,925 shares in the last quarter. Cantor Fitzgerald L. P. purchased a new stake in shares of Unicycive Therapeutics in the fourth quarter worth about $1,154,000. Finally, Geode Capital Management LLC boosted its holdings in Unicycive Therapeutics by 36.2% in the 4th quarter. Geode Capital Management LLC now owns 171,290 shares of the company’s stock valued at $989,000 after purchasing an additional 45,563 shares during the period. Institutional investors own 40.42% of the company’s stock.

Trending Headlines about Unicycive Therapeutics

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Piper Sandler reaffirmed a Buy on Unicycive, maintaining analyst support that can sustain demand among growth/biotech investors. Piper Sandler Remains a Buy on Unicycive Therapeutics (UNCY)
• Positive Sentiment: Guggenheim kept a Buy rating and a high $40 price target (down from $46), signaling continued bullish conviction and large upside vs. the current share price — a support for longer‑term investors. Benzinga
• Positive Sentiment: Coverage from Noble Financial includes a reportedly positive Q3 outlook and modest intraquarter upward tweaks, which may limit downside for near‑term earnings expectations. Noble Financial Has Positive Forecast for UNCY Q3 Earnings
• Neutral Sentiment: Noble Financial made small upward revisions to certain near‑term quarters (Q1 and a slight Q2 tweak), but also trimmed its FY2026 outlook — a mixed signal that tempers how much the stock should move on those changes alone.
• Negative Sentiment: HC Wainwright issued broad downgrades across Q2–Q4 2026 and materially cut FY2026–FY2030 EPS forecasts (FY2026 from ~($0.94) to ($1.67); FY2028–FY2030 reductions are especially large). Those cuts imply slower near‑term profitability and push out the path to the previously modeled upside, which is likely the main driver of downward pressure on the share price.
• Negative Sentiment: Noble also lowered its Q4 2026 and FY2026 numbers in the same reporting window, which adds further downward bias to consensus near‑term earnings expectations.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.